The impact of technical and clinical factors on fecal microbiota transfer outcomes for the treatment of recurrent Clostridioides difficile infections in Germany

被引:22
|
作者
Peri, Rosemarie [1 ,2 ]
Aguilar, Rebeca Cruz [1 ,2 ]
Tueffers, Kester [3 ]
Erhardt, Andreas [4 ]
Link, Alexander [5 ]
Ehlermann, Philipp [6 ]
Angeli, Wolfgang [7 ]
Frank, Thorsten [8 ]
Storr, Martin [9 ,10 ]
Gluck, Thomas [11 ]
Sturm, Andreas [12 ]
Rosien, Ulrich [13 ]
Tacke, Frank [14 ]
Bachmann, Oliver [15 ,16 ]
Solbach, Philipp [15 ,16 ]
Stallmach, Andreas [17 ]
Goeser, Felix [2 ,18 ]
Vehreschild, Maria J. G. T. [1 ,2 ,19 ]
机构
[1] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[2] German Ctr Infect Res DZIF, Bonn, Germany
[3] St Johannes Hosp, Dept Internal Med 2, Dortmund, Germany
[4] St Petrus Hosp, Dept Internal Med 2, Wuppertal, Germany
[5] Univ Hosp Magdeburg, Dept Gastroenterol Hepatol & Infect Dis, Magdeburg, Germany
[6] SRH Kurpfalzkrankenhaus Heidelberg, Dept Internal Med, Heidelberg, Germany
[7] Kempten Oberallgau Clin, Dept Gastroenterol, Kempten, Germany
[8] St Katharinen Hosp, Dept Internal Med 2, Frechen, Germany
[9] Ludwig Maximilians Univ Munchen, Dept Gastroenterol, Munich, Germany
[10] Ctr Endoscopy, Starnberg, Germany
[11] Trostberg Clin, Dept Internal Med, Trostberg, Germany
[12] DRK Kliniken Westend, Dept Internal Med & Gastroenterol, Berlin, Germany
[13] Israelit Hosp Hamburg, Visceral Med Ctr, Hamburg, Germany
[14] Univ Hosp Aachen, Dept Med 3, Aachen, Germany
[15] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany
[16] German Ctr Infect Res DZIF, Hannover, Germany
[17] Univ Hosp Jena, Dept Internal Med Gastroenterol Hepatol & Infecti, Jena, Germany
[18] Univ Hosp Bonn, Dept Internal Med 1, Bonn, Germany
[19] Univ Hosp Frankfurt, Dept Internal Med Infect Dis, Frankfurt, Germany
关键词
Fecal microbiota transfer; recurrent Clostridioides difficile infection; microbiota; risk factors; TRANSPLANTATION; PREDICTORS; EFFICACY; FAILURE; SOCIETY;
D O I
10.1177/2050640619839918
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction Fecal microbiota transfer (FMT) is highly effective in the treatment and prevention of recurrent Clostridioides difficile infection (rCDI) with cure rates of about 80% after a single treatment. Nevertheless, the reasons for failure in the remaining 20% remain largely elusive. The aim of the present study was to investigate different potential clinical predictors of response to FMT in Germany. Methods Information was extracted from the MicroTrans Registry (NCT02681068), a retrospective observational multicenter study, collecting data from patients undergoing FMT for recurrent or refractory CDI in Germany. We performed binary logistic regression with the following covariates: age, gender, ribotype 027, Eastern Co-operative Oncology Group score, immunosuppression, preparation for FMT by use of proton pump inhibitor, antimotility agents and bowel lavage, previous recurrences, severity of CDI, antibiotic induction treatment, fresh or frozen FMT preparation, and route of application. Results Treatment response was achieved in 191/240 evaluable cases (79.6%) at day 30 (D30) post FMT and 78.1% at day 90 (D90) post FMT. Assessment of clinical predictors for FMT failure by forward and confirmatory backward-stepwise regression analysis yielded higher age as an independent predictor of FMT failure (p = 0.001; OR 1.060; 95%CI 1.025-1.097). Conclusion FMT in Germany is associated with high cure rates at D30 and D90. No specific pre-treatment, preparation or application strategy had an impact on FMT success. Only higher age was identified as an independent risk factor for treatment failure. Based on these and external findings, future studies should focus on the assessment of microbiota and microbiota-associated metabolites as factors determining FMT success.
引用
收藏
页码:716 / 722
页数:7
相关论文
共 50 条
  • [31] Clostridioides difficile Infection in the Neurorehabilitation Setting: Importance of a Multidisciplinary Approach and Impact of the Fecal Microbiota Transplantation
    Secondo, Daniela
    Massaro, Dymytrii
    Verrienti, Giulio
    Perri, Francesco
    Biscaglia, Giuseppe
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (10)
  • [32] Physician and patient perceptions of fecal microbiota transplant for recurrent or refractory Clostridioides difficile in the first 6 years of a central stool bank
    Gill, Madeleine
    Blacketer, Charlotte
    Chitti, Franco
    Telfer, Karmen
    Papanicolas, Lito
    Dann, Lisa M.
    Tucker, Emily C.
    Bryant, Robert, V
    Costello, Samuel P.
    JGH OPEN, 2020, 4 (05): : 950 - 957
  • [33] Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-js']jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US
    Lodise, Thomas
    Guo, Amy
    Yang, Min
    Cook, Erin E.
    Song, Wei
    Yang, Danni
    Wang, Qingyuan
    Zhao, Angela
    Bochan, Markian
    ADVANCES IN THERAPY, 2023, 40 (06) : 2801 - 2819
  • [34] Risk Factors for Antibiotic Exposure Post-Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection: A Prospective Multicenter Observational Study
    Hirsch, William
    Fischer, Monika
    Khoruts, Alexander
    Allegretti, Jessica R.
    Kelly, Colleen R.
    Vaughn, Byron
    OPEN FORUM INFECTIOUS DISEASES, 2025, 12 (03):
  • [35] Epidemiology and Risk Factors of Clostridioides difficile Infections in Germany: A Health Claims Data Analysis
    Weinke, Thomas
    Beier, Dominik
    Brestrich, Gordon
    von Eiff, Christof
    Haeckl, Dennis
    Heinrich, Kirstin
    Moisi, Jennifer
    Schley, Katharina
    INFECTIOUS DISEASES AND THERAPY, 2023, 12 (05) : 1299 - 1317
  • [36] Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection
    de la Villa, Sofia
    Herrero, Sergio
    Munoz, Patricia
    Rodriguez, Carmen
    Valerio, Maricela
    Reigadas, Elena
    Alvarez-Uria, Ana
    Alcala, Luis
    Marin, Mercedes
    Olmedo, Maria
    Kestler, Martha
    Chamorro, Esther
    Bouza, Emilio
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (02):
  • [37] In Silico Analysis of Changes in Predicted Metabolic Capabilities of Intestinal Microbiota after Fecal Microbial Transplantation for Treatment of Recurrent Clostridioides difficile Infection
    Dahiya, Monica
    Jovel, Juan
    Monaghan, Tanya
    Wong, Karen
    Elhenawy, Wael
    Chui, Linda
    McAlister, Finlay
    Kao, Dina
    MICROORGANISMS, 2023, 11 (04)
  • [38] Epidemiology and Risk Factors of Clostridioides difficile Infections in Germany: A Health Claims Data Analysis
    Thomas Weinke
    Dominik Beier
    Gordon Brestrich
    Christof von Eiff
    Dennis Häckl
    Kirstin Heinrich
    Jennifer Moïsi
    Katharina Schley
    Infectious Diseases and Therapy, 2023, 12 : 1299 - 1317
  • [39] Derivation of clinical predictive factors (CHIEF) for first recurrent Clostridioides difficile infection
    Mori, Nobuaki
    Hirai, Jun
    Ohashi, Wataru
    Asai, Nobuhiro
    Shibata, Yuichi
    Mikamo, Hiroshige
    AMERICAN JOURNAL OF INFECTION CONTROL, 2024, 52 (04) : 419 - 423
  • [40] Impact of Clinical and Pharmacological Parameters on Faecal Microbiota Transplantation Outcome in Clostridioides difficile Infections: Results of a 5-Year French National Survey
    Benech, Nicolas
    Cassir, Nadim
    Alric, Laurent
    Barbut, Frederic
    Batista, Rui
    Bleibtreu, Alexandre
    Briot, Thomas
    Davido, Benjamin
    Galperine, Tatiana
    Joly, Anne-Christine
    Kapel, Nathalie
    Melchior, Chloe
    Mosca, Alexis
    Nebbad, Biba
    Pigneur, Benedicte
    Schneider, Stephane M.
    Wasiak, Mathieu
    Scanzi, Julien
    Sokol, Harry
    French Faecal Transplant Group GFTF
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025, 61 (01) : 159 - 167